US · Healthcare · Medical Devices
EPS came in at 1.14 against a street estimate of 1.07 — a beat of 6.5%.
Analysts rate Haemonetics Corporation a buy (8 buy, 1 hold, 1 sell out of 10) with an average price target of $108.40.
CONFIDENT HAE beat Q1 FY27 on broad-based growth across all three platforms. Raised full-year revenue and earnings guidance. Strong free cash flow conversion and balance sheet momentum support ongoing deleveraging and selective buybacks. Q1 FY27 OUS collections in Europe now represent 20% of total (vs. historical 10% level), reflecting customer globalization and HAE's expanded international footprint. Analysts pressed on Persona PLUS contribution magnitude, Vascular Closure competitive recovery mechanics, and Japan VASCADE timeline. Management clarified conservative guidance reflects only contracted commitments; emphasized Q1 benefited from market stabilization, better commercial execution, and clinical evidence rather than price cutting alone. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.35% |
| Neuberger Berman Group LLC | 7.83% |
| AQR Capital Management LLC | 7.38% |
| Vanguard Portfolio Management, LLC | 5.63% |
| Vanguard Capital Management, LLC | 4.59% |
| Ariel Investments, LLC | 4.53% |
| State Street Corp | 3.90% |
| Dimensional Fund Advisors, Inc. | 3.48% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q2 FY2027 HAEMONETICS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: August 18, 2026 • Agreement Date: August 14, 2026 • Company: Haemonetics | 2026-08-18 |
| Quarterly report · Q1 FY2027 HAEMONETICS CORPORATION – Q1 FY2027 10-Q SUMMARY HEADLINE NUMBERS • Net revenues (Q1 FY2027): $339.4 million, up 5.6% vs. $321.4 million in Q1 FY202 | 2026-08-06 |
| Results announced · Q2 FY2027 HAEMONETICS CORPORATION – Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue: $339.4 million, up 5.6% vs. prior year Q1 • Organic revenue g | 2026-08-06 |
| Board / officer change · Q1 FY2027 HAEMONETICS CORPORATION (HAE) - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Haemonetics Corporation is a medical device company headquartered i | 2026-07-28 |
| Proxy statement · Q4 FY2026 HAEMONETICS CORPORATION – PROXY STATEMENT SUMMARY HEADLINE NUMBERS • Fiscal 2026: Met or exceeded nearly all total company financial targets despite | 2026-06-09 |
| Reg FD disclosure · Q1 FY2027 HAEMONETICS CORPORATION (HAE) – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Segment Restructuring Announced: Company is reorganizing its report | 2026-06-05 |
| Annual report FY2026 HAEMONETICS CORPORATION – FISCAL YEAR 2026 10-K SUMMARY HEADLINE NUMBERS • Fiscal year ended March 28, 2026 • Market capitalization as of September | 2026-05-20 |
| Quarterly report · Q3 FY2026 HAEMONETICS CORPORATION – Q3 FY2026 10-Q SUMMARY HEADLINE NUMBERS • Q3 FY2026 Net Revenue: $338,967 thousand vs. $348,542 thousand in Q3 FY2025 (dow | 2026-02-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Supply agreement with CSL Plasma for device and disposable sales Haemonetics Corporation signed a non-exclusive supply agreement with CSL Plasma Inc. on August 14, 2026, allowing CSL to purchase Haemonetics' NexSys PCS devices with Persona PLUS technology | 2026-08-18 |
| Acquisition of Vivasure Medical for vessel closure technology Haemonetics Corporation announced on January 9, 2026, that it acquired Vivasure Medical Limited, an Ireland-based company specializing in next-generation percutaneous vessel closure technolo | 2026-01-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Haemonetics Corporation — free to start.
Google PlayApp StoreData updated 2026-09-18.